US 11,795,144 B2
Inhibitors of RAC1 and uses thereof for treating cancers
Vincent Sauzeau, Bouguenais (FR); Gervaise Loirand, Thouare-sur-Loire (FR); Jacques Lebreton, Nantes (FR); Arnaud Tessier, Orvault (FR); and Agnès Quemener, Nantes (FR)
Assigned to INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Paris (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris (FR); UNIVERSITE DE NANTES, Nantes (FR); and CHU NANTES, Nantes (FR)
Appl. No. 16/619,311
Filed by INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Paris (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris (FR); UNIVERSITE DE NANTES, Nantes (FR); and CHU NANTES, Nantes (FR)
PCT Filed Jun. 6, 2018, PCT No. PCT/EP2018/064928
§ 371(c)(1), (2) Date Dec. 4, 2019,
PCT Pub. No. WO2018/224563, PCT Pub. Date Dec. 13, 2018.
Claims priority of application No. 17305664 (EP), filed on Jun. 6, 2017.
Prior Publication US 2020/0095199 A1, Mar. 26, 2020
Int. Cl. A61P 35/00 (2006.01); C07C 311/29 (2006.01)
CPC C07C 311/29 (2013.01) [A61P 35/00 (2018.01)] 4 Claims
 
1. A method for the treatment of cancer, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound having the following formula (VII):

OG Complex Work Unit Chemistry
wherein:
p is an integer from 1 to 3 inclusive;
X′ is chosen from the group consisting of: —S—, —NH—, —NRd—, —CH2—, —SO2—, and —SO—, Rd being H or a (C1-C6)alkyl group;
R5 is a (C1-C6)alkyl group; and
the R4 groups, identical or different, are chosen from the (C1-C6)alkyl groups.